Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models.

Abstract:

BACKGROUND AND AIMS:Acute-on-chronic liver failure (ACLF) is a progressive disease associated with rapid clinical worsening and high mortality. Early prediction of mortality and intervention can improve patient outcomes. We aimed to develop a dynamic prognostic model and compare it with the existing models. METHODS:A total of 1402 ACLF patients, enrolled in the APASL-ACLF Research Consortium (AARC) with 90-day follow-up, were analyzed. An ACLF score was developed in a derivation cohort (n = 480) and was validated (n = 922). RESULTS:The overall survival of ACLF patients at 28 days was 51.7%, with a median of 26.3 days. Five baseline variables, total bilirubin, creatinine, serum lactate, INR and hepatic encephalopathy, were found to be independent predictors of mortality, with AUROC in derivation and validation cohorts being 0.80 and 0.78, respectively. AARC-ACLF score (range 5-15) was found to be superior to MELD and CLIF SOFA scores in predicting mortality with an AUROC of 0.80. The point scores were categorized into grades of liver failure (Gr I: 5-7; II: 8-10; and III: 11-15 points) with 28-day cumulative mortalities of 12.7, 44.5 and 85.9%, respectively. The mortality risk could be dynamically calculated as, with each unit increase in AARC-ACLF score above 10, the risk increased by 20%. A score of ≥11 at baseline or persisting in the first week was often seen among nonsurvivors (p = 0.001). CONCLUSIONS:The AARC-ACLF score is easy to use, dynamic and reliable, and superior to the existing prediction models. It can reliably predict the need for interventions, such as liver transplant, within the first week.

journal_name

Hepatol Int

journal_title

Hepatology international

authors

Choudhury A,Jindal A,Maiwall R,Sharma MK,Sharma BC,Pamecha V,Mahtab M,Rahman S,Chawla YK,Taneja S,Tan SS,Devarbhavi H,Duan Z,Yu C,Ning Q,Jia JD,Amarapurkar D,Eapen CE,Goel A,Hamid SS,Butt AS,Jafri W,Kim DJ,G

doi

10.1007/s12072-017-9816-z

subject

Has Abstract

pub_date

2017-09-01 00:00:00

pages

461-471

issue

5

eissn

1936-0533

issn

1936-0541

pii

10.1007/s12072-017-9816-z

journal_volume

11

pub_type

杂志文章
  • Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis.

    abstract:BACKGROUND/AIMS:[corrected] The risk of hepatocellular carcinoma (HCC) increased with progression of hepatic fibrosis as assessed by liver stiffness measurement (LSM). This study used LSM to assess the risk of HCC presence in patients with chronic hepatitis. METHODS:The patients with liver tumor or chronic hepatitis i...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-010-9223-1

    authors: Kuo YH,Lu SN,Hung CH,Kee KM,Chen CH,Hu TH,Lee CM,Changchien CS,Wang JH

    更新日期:2010-10-08 00:00:00

  • Different aspects of CD4 T cells that lead to viral clearance or persistence of HCV infection.

    abstract::More than 170 million people worldwide are infected with hepatitis C virus (HCV). A characteristic of this virus is a high tendency toward chronic infection. Several factors affect the viral outcome after infection. Among them, HCV-specific CD4 T cells are thought to play a crucial role in controlling viremia. Cumulat...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-011-9321-8

    authors: Sugimoto K,Shiraki K

    更新日期:2012-01-01 00:00:00

  • An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.

    abstract:AIM:Tamibarotene is a synthetic retinoid expected to inhibit tumor-cell proliferation and to induce apoptosis by selective interaction with retinoic acid receptor α/β. We conducted an open-label phase I/II study to determine the maximum tolerated dose (MTD) and recommended dose (RD), and to evaluate the pharmacokinetic...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9459-7

    authors: Kanai F,Obi S,Fujiyama S,Shiina S,Tamai H,Mochizuki H,Koike Y,Imamura J,Yamaguchi T,Saida I,Yokosuka O,Omata M

    更新日期:2014-01-01 00:00:00

  • Predictors of outcome in acute-on-chronic liver failure in children.

    abstract:BACKGROUND AND AIMS:Acute-on-chronic liver failure (ACLF) is associated with a high mortality rate in the absence of liver transplantation. There is limited data on predictors of survival in ACLF in children. Therefore, we prospectively studied the predictors of outcome of ACLF in children. METHODS:A prospective evalu...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-010-9217-z

    authors: Lal J,Thapa BR,Rawal P,Ratho RK,Singh K

    更新日期:2011-06-01 00:00:00

  • Hepatic encephalopathy in acute-on-chronic liver failure.

    abstract::The presence of hepatic encephalopathy (HE) within 4 weeks is part of the criteria for defining acute-on-chronic liver failure (ACLF). The pathophysiology of HE is complex, and hyperammonemia and cerebral hemodynamic dysfunction appear to be central in the pathogenesis of encephalopathy. Recent data also suggest that ...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-015-9626-0

    authors: Lee GH

    更新日期:2015-10-01 00:00:00

  • Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments.

    abstract::The prognosis of advanced hepatocellular carcinoma (HCC) remains poor. For patients with advanced HCC, the multikinase inhibitor sorafenib is recommended as the current standard of care. In contrast, hepatic arterial infusion chemotherapy (HAIC) is one of the recommended treatments in Japan. However, in Japan, the use...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9515-3

    authors: Yamasaki T,Saeki I,Sakaida I

    更新日期:2014-09-01 00:00:00

  • A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.

    abstract:PURPOSE:Hepatitis B viral markers may be useful for predicting outcomes such as liver-related deaths or development of hepatocellular carcinoma. We determined the frequency of these markers in different clinical stages of chronic hepatitis B infection. METHODS:We compared baseline hepatitis B viral markers in 317 pati...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-010-9179-1

    authors: Tong MJ,Hsu L,Hsien C,Kao JH,Durazo FA,Saab S,Blatt LM

    更新日期:2010-04-07 00:00:00

  • Effect of hepatitis B surface antibody in patients with core antibody-positive liver transplantation: a systematic review and meta-analysis.

    abstract:BACKGROUND AND AIM:There is an increased awareness of de novo hepatitis B virus (HBV) infection (DNH) in hepatitis B surface antigen (HBsAg)-negative recipients receiving hepatitis B core antibody (HBcAb)-positive liver organ. Whether hepatitis B surface antibody (HBsAb) has positive result on preventing the occurrence...

    journal_title:Hepatology international

    pub_type: 杂志文章,meta分析

    doi:10.1007/s12072-020-10021-5

    authors: Yang Y,Huang A,Zhao Y

    更新日期:2020-03-01 00:00:00

  • An imbalance between stellate cells and γδT cells contributes to hepatocellular carcinoma aggressiveness and recurrence.

    abstract:PURPOSE:The diagnostic potential of hepatic stellate cells (HSCs) and γδT cells for patients with hepatocellular carcinoma (HCC) and their synergistic contributions to the prognosis of these patients have not yet been investigated. The aim of this study was to elucidate the prognostic value of these cells in HCC. METH...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-09969-w

    authors: Zhou BY,Gong JH,Cai XY,Wang JX,Luo F,Jiang N,Gong JP,Du CY,Liao R

    更新日期:2019-09-01 00:00:00

  • Virus-induced hepatocellular carcinoma with special emphasis on HBV.

    abstract::Hepatocellular carcinoma (HCC) is a common malignant tumor with high lethality, and the hepatitis B virus (HBV) is a chief cause. HBV can accelerate HCC via multiple mechanisms. First, HBV induces immune reactions that lead to repeated hepatic inflammation, fibrosis and a deficient immune microenvironment. Subsequentl...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-016-9779-5

    authors: Wang M,Xi D,Ning Q

    更新日期:2017-03-01 00:00:00

  • Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.

    abstract:BACKGROUND:Controversy exists on whether tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) in lowering the risk of hepatocellular carcinoma (HCC) development. This meta-analysis was performed to clarify this issue with critical clinical and methodological considerations. METHODS:PubMed, EMBASE, and Co...

    journal_title:Hepatology international

    pub_type: 杂志文章,meta分析

    doi:10.1007/s12072-019-10005-0

    authors: Li M,Lv T,Wu S,Wei W,Wu X,Ou X,Ma H,Chow SC,Kong Y,You H,Jia J

    更新日期:2020-01-01 00:00:00

  • Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis.

    abstract:BACKGROUND/PURPOSE:Gut microbiota has been associated with liver cirrhosis and, possibly, hepatic encephalopathy. However, only a few studies have examined the link between mucosa-associated microbiota (MAM) and minimal hepatic encephalopathy (MHE). Our aim was to investigate this relationship. METHODS:Twenty-four pat...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-09963-2

    authors: Haraguchi M,Miuma S,Masumoto H,Ichikawa T,Kanda Y,Sasaki R,Fukushima M,Miyaaki H,Taura N,Nakao K

    更新日期:2019-07-01 00:00:00

  • The effect of systemic antibiotic prophylaxis for cirrhotic patients with peptic ulcer bleeding after endoscopic interventions.

    abstract:PURPOSE:All previous studies reported the benefit of antibiotic prophylaxis in cirrhotic patients with either a mixture of nonvariceal and variceal bleeding or variceal bleeding alone. Reports on sole peptic ulcers bleeding are lacking. We aimed to assess the effect of antibiotic prophylaxis in cirrhotic patients with ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-012-9378-z

    authors: Yang SC,Wu KL,Wang JH,Lee CH,Kuo YH,Tai WC,Chen CH,Chiou SS,Lu SN,Hu TH,Changchien CS,Chuah SK

    更新日期:2013-03-01 00:00:00

  • Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region.

    abstract:BACKGROUND AND AIM:Cirrhosis is a controversial determinant of mortality in HBV-related acute-on-chronic liver failure (HBV-ACLF). The present study aimed to explore the effects of cirrhosis and the associated risk factors, especially its complications, on the outcome of HBV-ACLF. METHODS:A prospective-retrospective c...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-09992-x

    authors: Chen T,Yang Z,Choudhury AK,Al Mahtab M,Li J,Chen Y,Tan SS,Han T,Hu J,Hamid SS,Huei LG,Ghazinian H,Nan Y,Chawla YK,Yuen MF,Devarbhavi H,Shukla A,Abbas Z,Sahu M,Dokmeci AK,Lesmana LA,Lesmana CRA,Xin S,Duan Z,

    更新日期:2019-11-01 00:00:00

  • Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries.

    abstract:PURPOSE:The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party to develop a consensus cost-effectiveness model for treatment of Hepatitis B in Asia Pacific countries in March 2010. METHODS:The working party consisted of expert hepatologists, virologists and epidemiolog...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-014-9549-1

    authors: Dan YY,Wong JB,Hamid SS,Han KH,Jia JD,Liu CJ,Piratvisuth T,Lok AS,Lim SG

    更新日期:2014-07-01 00:00:00

  • Role of free radicals in liver diseases.

    abstract::Reactive oxygen and nitrogen species (ROS and RNS) are produced by metabolism of normal cells. However, in liver diseases, redox is increased thereby damaging the hepatic tissue; the capability of ethanol to increase both ROS/RNS and peroxidation of lipids, DNA, and proteins was demonstrated in a variety of systems, c...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-009-9158-6

    authors: Muriel P

    更新日期:2009-12-01 00:00:00

  • Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion.

    abstract:PURPOSE:Microvascular invasion of hepatocellular carcinoma (HCC) is considered a poor prognostic factor of liver resection (LR) and liver transplantation (LT), but its significance for lesions within the up-to-7 criteria is unclear. This study investigated the survival benefit of primary LT against LR for HCC with micr...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-011-9318-3

    authors: Chan SC,Fan ST,Chok KS,Cheung TT,Chan AC,Fung JY,Poon RT,Lo CM

    更新日期:2011-10-21 00:00:00

  • MSC-based therapies in solid organ transplantation.

    abstract::Immunomodulatory cell therapy as a complement to standard pharmacotherapy represents a novel approach to solid organ allograft acceptance. This methodology may allow for a reduced dose of immunosuppressive drug to be administered and thus attenuate the severe side effects associated with long-term immunosuppression su...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9509-1

    authors: Benseler V,Obermajer N,Johnson CL,Soeder Y,Dahlke MD,Popp FC

    更新日期:2014-04-01 00:00:00

  • Hepatocellular adenoma: what is new in 2008.

    abstract::Patients (85%) with hepatocellular adenoma (HCA) are women taking oral contraceptives. They can be divided into four subgroups according to their genotype/phenotype features. (1) Hepatocyte nuclear factor 1alpha (HNF1alpha) biallelic somatic mutations are observed in 35% of the HCA cases. It occurs in almost all cases...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-008-9075-0

    authors: Bioulac-Sage P,Laumonier H,Laurent C,Zucman-Rossi J,Balabaud C

    更新日期:2008-09-01 00:00:00

  • Actinomycotic hepatic abscess.

    abstract::Actinomycotic hepatic abscess was diagnosed in a 46-year-old male driver from Ukraine presenting with the symptoms of malaise, loss of appetite, upper right quadrant pain, weight loss, and night sweats which had been present for last 2 months. Computed tomography (CT) of the abdomen revealed a hypodense mass in the le...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-007-9032-3

    authors: Tiftikci A,Vardareli EN,Kaban K,Peker O,Akansel S,Tozun N

    更新日期:2008-03-01 00:00:00

  • Interferon gamma, interleukin-6, and -17a levels were correlated with minimal hepatic encephalopathy in HBV patients.

    abstract:BACKGROUND AND OBJECTIVE:Cytokines have been reported to be involved in the cirrhosis and hepatic encephalopathy (HE). Many aspects on the correlation between minimal HE (MHE) and cytokine levels were still unclear. METHODS:Two hundred eighty-nine HBV-infected cirrhotic patients were grouped: non MHE (n = 156), MHE (n...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-015-9610-8

    authors: Li W,Li N,Wang R,Li Q,Wu H

    更新日期:2015-04-01 00:00:00

  • Immunological cure of HBV infection.

    abstract::Chronic hepatitis B virus (HBV) infection is a major global health burden and cure is rarely achieved by current antiviral therapies. Therefore, there is an urgent need for new therapeutic options. Immune modulation with the goal to restore dysfunctional HBV-specific immunity is an interesting target for new therapeut...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-018-9912-8

    authors: Lang J,Neumann-Haefelin C,Thimme R

    更新日期:2019-03-01 00:00:00

  • Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure.

    abstract:BACKGROUND AND AIMS:T cell-mediated immune injury plays a critical role in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Given the high short-term mortality and crucial role of T cells in the disease progression, it is necessary to investigate the dynamics of T cell clones dur...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-10008-x

    authors: Shen G,Sun S,Huang J,Deng H,Xu Y,Wang Z,Tang X,Gong X

    更新日期:2020-01-01 00:00:00

  • Prognostic analysis of pulmonary metastases from hepatocellular carcinoma.

    abstract:PURPOSE:To analyze the prognostic factors for the patients with lung metastases from hepatocellular carcinoma (HCC). METHODS AND MATERIALS:One hundred and five patients with lung metastases from HCC were analyzed retrospectively. We analyzed the impact factors, including the gender, age, liver function, serum AFP and ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-008-9052-7

    authors: Zhang SM,Zeng ZC,Tang ZY,Sun J,Cheng JM,Liu R,Wang P,Zhang BH

    更新日期:2008-06-01 00:00:00

  • A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients.

    abstract:PURPOSE:To compare the efficacy of entecavir (ETV) monotherapy up to 4 years in nucleos(t)ide analog (NA)-experienced and -naïve subjects. METHODS:One hundred sixty NA-experienced and 282 naïve chronic hepatitis B patients who were treated with ETV were enrolled. Of the 160 NA-experienced patients, 49 had prior lamivu...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9440-5

    authors: Chen CH,Hu TH,Hung CH,Lu SN,Wang JH,Chang MH,Changchien CS,Lee CM

    更新日期:2013-07-01 00:00:00

  • Pharmacologic prevention of variceal bleeding and rebleeding.

    abstract:BACKGROUND:Variceal bleeding is a major complication of portal hypertension, which is associated with significant mortality. Moreover, patients surviving a variceal bleeding episode have very high risk of rebleeding, which is associated with mortality as high as that of the first bleed. Because of this, prevention of b...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-017-9833-y

    authors: Baiges A,Hernández-Gea V,Bosch J

    更新日期:2018-02-01 00:00:00

  • C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3.

    abstract:BACKGROUND:The aim of our study was to explore how C1QTNF1-AS1 regulated miR-221-3p/SOCS3 axis in human hepatocellular carcinoma (HCC). METHODS:Differentially expressed lncRNAs and genes were examined via RNA-seq. GO analysis and KEGG pathway enrichment analysis were carried out based on the function of dys-regulated ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-09944-5

    authors: Li H,Zhang B,Ding M,Lu S,Zhou H,Sun D,Wu G,Gan X

    更新日期:2019-05-01 00:00:00

  • A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan.

    abstract::In a country such as Japan with the average age of patients with chronic hepatitis C treated with antivirals sometimes well above 60 years, the standard combination therapy is not well tolerated. In this randomized, prospective, controlled trial, we investigated the efficacy of 24-week peginterferon α monotherapy for ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-009-9134-1

    authors: Iwasaki Y,Shiratori Y,Hige S,Nishiguchi S,Takagi H,Onji M,Yoshida H,Izumi N,Kohgo Y,Yamamoto K,Sato N,Shibuya A,Saito H,Sata M,Suzuki K,Kaneko S,Moriyama M,Omata M

    更新日期:2009-09-01 00:00:00

  • Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study.

    abstract:PURPOSE:There have been reports that radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) is as equally effective as surgical resection for the treatment of hepatocellular carcinoma (HCC). This study aimed to evaluate recurrence rate and risk factor of recurrence after RFA combined with TA...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-011-9290-y

    authors: Kim JH,Yim HJ,Lee KG,Kim SY,Jung ES,Jung YK,Kim JH,Seo YS,Yeon JE,Lee HS,Um SH,Byun KS,Ryu HS

    更新日期:2012-04-01 00:00:00

  • Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study.

    abstract:BACKGROUND:Compositional changes of the gut microbiota are known to occur in patients with nonalcoholic fatty liver disease (NAFLD); however, the changes did not corroborate between the studies. We evaluated the gut microbiota between NAFLD and non-NAFLD participants, excluding the influence of obesity and sex in this ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-09987-8

    authors: Iino C,Endo T,Mikami K,Hasegawa T,Kimura M,Sawada N,Nakaji S,Fukuda S

    更新日期:2019-11-01 00:00:00